Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...3132333435363738394041...208209»
  • ||||||||||  Review, Journal:  Advancements in Dalpiciclib for the Treatment of Breast Cancer Patients: A Review. (Pubmed Central) -  Jul 7, 2025   
    The researches about dalpiciclib with different anti-tumor drugs are ongoing to explore the efficacy and the best strategies to use dalpiciclib. This review provides an overview of the research progress on dalpiciclib across different breast cancer subtypes with various anti-tumor drugs in different treatment opportunities.
  • ||||||||||  Review, Journal:  HER2 alterations in non-small cell lung cancer (NSCLC): from biology and testing to advances in treatment modalities. (Pubmed Central) -  Jul 7, 2025   
    Furthermore, we present updated clinical trial data for published HER2-targeted agents and explore ongoing clinical trials examining combinatorial therapies and next-generation HER2-targeted agents such as zongertinib, A166, ARX788, SHRA1811, and others. Given the rapid evolution in this field, our review offers a timely and comprehensive synthesis of the current state and future directions for HER2-altered NSCLC.
  • ||||||||||  Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker:  Research letter: immune checkpoint inhibitors against thyroid cancer. (Pubmed Central) -  Jul 3, 2025   
    Our analysis has revealed that, for neoadjuvant therapy in AGC, the mesenchymal subtype stands out as the ideal patient population benefiting from Apatinib. The study presents some valuable insights regarding the present state and future perspectives of clinical trials on thyroid cancer.
  • ||||||||||  HR17031 / Jiangsu Hengrui Pharma
    Trial primary completion date:  A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes (clinicaltrials.gov) -  Jul 3, 2025   
    P3,  N=401, Active, not recruiting, 
    Findings from this phase 2 trial suggest that an oral GnRH antagonist could be an effective alternative for preventing a premature LH surge in ART. Trial primary completion date: Mar 2025 --> Aug 2025
  • ||||||||||  HRS9531 injection / Kailera Therapeutics
    Efficacy and safety of HRS9531, a novel dual GLP-1/GIP receptor agonist in Chinese overweight or obese adults without diabetes (Sofia Hall) -  Jul 1, 2025 - Abstract #EASD2025EASD_514;    
    P2
    INS068 demonstrated similar efficacy as IGlar, with significantly lower incidence of overall hypoglycemia and overall nocturnal hypoglycemia after 52-week treatment, in uncontrolled T2D with OADs in China. In overweight or obese adults without diabetes, once-weekly subcutaneous HRS9531 significantly reduced body weight at week 36 compared to placebo and demonstrated a manageable safety profile, primarily involving gastrointestinal disorders.
  • ||||||||||  remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
    Trial completion date, Trial primary completion date, Intubation:  Study on the Safety and Effectiveness of Remimazolam Tosilate for Injection for Short-term Elective Surgery in Adults (clinicaltrials.gov) -  Jun 30, 2025   
    P4,  N=650, Completed, 
    In overweight or obese adults without diabetes, once-weekly subcutaneous HRS9531 significantly reduced body weight at week 36 compared to placebo and demonstrated a manageable safety profile, primarily involving gastrointestinal disorders. Trial completion date: Jan 2023 --> May 2025 | Trial primary completion date: Dec 2022 --> Mar 2025
  • ||||||||||  Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker:  Long-term immune checkpoint inhibitor therapy in a patient with metastatic nasopharyngeal carcinoma: a case report. (Pubmed Central) -  Jun 27, 2025   
    Alternatively, for specific ICIs, including nivolumab, camrelizumab, and tislelizumab, continuous administration until disease progression has emerged as a favored approach...The patient completed two cycles of induction chemotherapy with liposomal paclitaxel and nedaplatin, followed by platinum-based concurrent chemoradiotherapy, resulting in a progression-free survival (PFS) of 23.6 months...EBV DNA levels could serve as an informative marker to predict the necessity of therapy discontinuation during immunotherapy maintenance. Notably, a post-discontinuation ICI rechallenge can still yield favorable outcomes potentially accredited to immune memory.
  • ||||||||||  AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
    Enrollment open:  Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC (clinicaltrials.gov) -  Jun 27, 2025   
    P2,  N=48, Recruiting, 
    N=180 --> 110 | Recruiting --> Terminated; The sponsor's R&D strategy is adjusted. Not yet recruiting --> Recruiting
  • ||||||||||  SHR0410 / Jiangsu Hengrui Pharma
    Enrollment change, Trial termination:  A Trial of SHR0410 Injection in Postsurgical Pain Management (clinicaltrials.gov) -  Jun 27, 2025   
    P2,  N=31, Terminated, 
    Trial completion date: Feb 2028 --> Dec 2028 | Trial primary completion date: Apr 2027 --> Feb 2028 N=108 --> 31 | Recruiting --> Terminated; Adjustment of R&D strategy
  • ||||||||||  AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
    Enrollment change, Trial termination:  A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC (clinicaltrials.gov) -  Jun 27, 2025   
    P2,  N=20, Terminated, 
    N=108 --> 31 | Recruiting --> Terminated; Adjustment of R&D strategy N=144 --> 20 | Active, not recruiting --> Terminated; The sponsor's R&D strategy is adjusted.